Wall Street analysts expect that Luminex Co. (NASDAQ:LMNX) will report $0.11 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Luminex’s earnings, with the lowest EPS estimate coming in at $0.09 and the highest estimate coming in at $0.14. Luminex posted earnings per share of $0.17 in the same quarter last year, which indicates a negative year over year growth rate of 35.3%. The company is expected to issue its next quarterly earnings results on Monday, February 11th.

On average, analysts expect that Luminex will report full-year earnings of $0.55 per share for the current year, with EPS estimates ranging from $0.54 to $0.56. For the next fiscal year, analysts anticipate that the company will post earnings of $0.54 per share, with EPS estimates ranging from $0.32 to $0.66. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that cover Luminex.

Luminex (NASDAQ:LMNX) last released its quarterly earnings results on Monday, November 5th. The medical instruments supplier reported $0.05 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.08 by ($0.03). Luminex had a return on equity of 5.99% and a net margin of 5.65%. The company had revenue of $72.40 million for the quarter, compared to analysts’ expectations of $74.05 million. During the same quarter last year, the company earned $0.13 EPS. Luminex’s revenue for the quarter was down 2.3% compared to the same quarter last year.

Several research analysts have issued reports on LMNX shares. Citigroup cut their price objective on Luminex from $34.00 to $33.00 and set a “neutral” rating for the company in a research report on Tuesday. BidaskClub cut Luminex from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 22nd. Zacks Investment Research cut Luminex from a “hold” rating to a “sell” rating in a research report on Wednesday, August 8th. Finally, ValuEngine upgraded Luminex from a “buy” rating to a “strong-buy” rating in a research report on Monday, October 29th. Five investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $28.40.

NASDAQ:LMNX traded down $0.47 during trading hours on Monday, hitting $26.61. The company’s stock had a trading volume of 306,857 shares, compared to its average volume of 300,699. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of 29.24, a PEG ratio of 3.26 and a beta of 0.34. Luminex has a 52-week low of $18.62 and a 52-week high of $35.37.

The company also recently announced a quarterly dividend, which was paid on Friday, October 12th. Shareholders of record on Friday, September 21st were issued a $0.06 dividend. This represents a $0.24 annualized dividend and a yield of 0.90%. The ex-dividend date of this dividend was Thursday, September 20th. Luminex’s dividend payout ratio (DPR) is 26.37%.

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. raised its holdings in shares of Luminex by 0.8% in the 3rd quarter. BlackRock Inc. now owns 6,644,013 shares of the medical instruments supplier’s stock worth $201,379,000 after purchasing an additional 50,973 shares during the period. Thomson Horstmann & Bryant Inc. raised its holdings in shares of Luminex by 16.5% during the 3rd quarter. Thomson Horstmann & Bryant Inc. now owns 514,162 shares of the medical instruments supplier’s stock valued at $15,584,000 after buying an additional 72,831 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Luminex by 26,778.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 221,476 shares of the medical instruments supplier’s stock valued at $6,712,000 after buying an additional 220,652 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Luminex by 1.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 682,988 shares of the medical instruments supplier’s stock valued at $20,701,000 after buying an additional 10,250 shares during the period. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in shares of Luminex during the 3rd quarter valued at about $227,000. 82.36% of the stock is currently owned by institutional investors.

Luminex Company Profile

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.

Featured Article: What Are Treasury Bonds?

Get a free copy of the Zacks research report on Luminex (LMNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.